Comparing Different Anti-angiogenic Agents and TKI Combinations in EGFR-mutated Advanced NSCLC: a Retrospective Study

The combination of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with either bevacizumab or ramucirumab, both anti-angiogenic agents, has demonstrated superior efficacy in progression-free survival (PFS) than TKI monotherapy in EGFR-mutated non-small cell lung cancer (NSCLC). The clinical applications, efficacy, and adverse events of these two different dual combinations in real-world practice remain unknown.